Supplementary Table 1. Demographic characteristics of women with lupus by treatment status with cyclophosphamide including women who had a hysterectomy before the age of 40

		Ever received Cyclophosphamide					
		Ye	<u>s</u>	<u> </u>	<u>Vo</u>	P-value	
Demographic and clinical cha	racteristics	N=42	22%	N=145	78%		
Age at survey	40 - 49	26	62%	80	55%	0.45	
	50 - 59	14	33%	44	30%		
	60 - 69	2	5%	19	13%		
	70 - 79	0	0%	2	1%		
Age at diagnosis	20 - 24	10	24%	24	17%	0.16	
	25 - 29	8	19%	36	25%		
	30 - 34	15	36%	34	23%		
	35 - 39	9	21%	51	35%		
Race/ ethnicity	Non-Hispanic white	4	10%	28	19%	0.32	
	Non-Hispanic black	35	83%	106	73%		
	Other	3	7%	11	8%		
Current marital status	Married	18	43%	62	43%	0.40	
	Never married	14	33%	35	24%		
	Other ¹	10	24%	47	33%		
Education	High school or less	6	15%	47	33%	0.02	
	More than high school	35	85%	94	67%		
Annual household income	Less than \$20,000	10	26%	48	36%	0.59	
	\$20,000 - \$39,999	8	21%	25	19%		
	\$40,000 - \$69,999	10	26%	24	18%		
	\$70,000 or more	11	28%	37	28%		
Insurance	Private	19	50%	65	50%	0.19	
	Medicare	14	37%	32	25%		
	Medicaid	5	13%	33	25%		
BILD score	0	5	12%	38	26%	0.06	
	1	8	19%	25	17%		
	2-3	12	29%	50	34%		
	≥ 4	17	40%	32	22%		
Secondary amenorrhea before	Yes, not due to a hysterectomy	13	31%	19	13%	0.01	
age 40	Yes, due to a hysterectomy	9	21%	31	21%		

1					ı
No	20	48%	95	66%	

¹Includes separated, divorced, and living with a partner (not married)

Supplementary Table 2. Reproductive health by cyclophosphamide status and self-report of early secondary amenorrhea including women who had a hysterectomy before the age of 40 in the "No early amenorrhea" group

		Ever received Cyclophosphamide			Never received Cyclophosphamide						
		Early secondary amenorrhea		No early amenorrhea P-value		Early secondary amenorrhea		No early <u>amenorrhea¹</u>		P-value	
		N=12 ²	33%	N=24	67%		N=17	13%	N=113	87%	
Pregnant ever	Yes	7	64%	23	96%	0.03	15	88%	105	93%	0.62
	No	4	36%	1	4%		2	12%	8	7%	
Pregnancies before lupus	0	6	55%	3	13%	0.02	2	13%	17	16%	1.00
	1	3	27%	7	29%		4	25%	27	26%	
	2 or more	2	18%	14	53%		10	63%	61	58%	
Pregnancies after lupus	0	7	70%	14	70%	1.00	5	29%	12	12%	0.16
	1	2	20%	3	15%		4	24%	26	26%	
	2 or more	1	10%	3	15%		8	47%	63	62%	
Total number of children	0	5	45%	3	14%	0.14	5	29%	12	13%	0.17
	1	4	36%	8	38%		4	16%	21	22%	
	2 or more	2	18%	10	48%		8	47%	62	65%	
Children before lupus	0	6	60%	4	19%	0.09	5	31%	22	23%	0.78
	1	3	30%	9	43%		4	25%	30	30%	
	2 or more	1	10%	8	38%		7	44%	45	46%	
Children after lupus	0	9	82%	18	86%	1.00	13	76%	72	71%	0.92
	1	1	9%	2	10%		2	12%	18	18%	
	2 or more	1	9%	1	5%		2	12%	11	11%	

Supplemental Table 3. Comparison of the prevalence of early secondary amenorrhea, ever being pregnant, and ever having a child by cyclophosphamide status and whether the women experienced early menopause including women who had a hysterectomy before the age of 40 in the "No early amenorrhea" group

		Experiencing early se	condary amenorrhea	Ever being	pregnant	Ever having a child		
		Crude PR (95% CI)	Adj. PR (95% CI) ¹	Crude PR (95% CI)	Adj. PR (95% CI) ²	Crude PR (95% CI)	Adj. PR (95% CI) ²	
Ever treated with	Yes	2.4 (1.3 - 4.7)	2.6(1.3-5.1)	0.9 (0.8 - 1.1)	0.8 (0.7 - 1.0)	0.9 (0.7 - 1.1)	0.9 (0.7 - 1.0)	
cyclophosphamide	No	ref	ref	ref	ref	ref	ref	
Experienced early	Yes	-	-	0.8 (0.6 - 1.0)	0.9 (0.7 - 1.1)	0.7(0.5-0.9)	0.8 (0.6 - 1.1)	
secondary amenorrhea	No	-	-	ref	ref	ref	ref	

¹A Poisson regression model with a robust variance was used and was adjusted for age at diagnosis, race, education level, income, marital status, current insurance, and BILD score

¹This group includes women who reported no early amenorrhea and those who reported early amenorrhea was experienced due to a hysterectomy. ²A number of women in each group had incomplete pregnancy data so column totals represent the number of women with at least some pregnancy information but may not equal the total number of women in each outcome category

²A Poisson regression model with a robust variance was used to estimate the effect of treatment with cyclophosphamide and was adjusted for age at diagnosis, race, education level, income, marital status, current insurance, and BILD score. A similar model was used to estimate the effect of early secondary amenorrhea, but was also adjusted for treatment with cyclophosphamide.

Supplementary Table 4. Association between demographic and clinical characteristics and early secondary amenorrhea among women who were not treated with cyclophosphamide including women who had a hysterectomy before the age of 40 in the "No early

amenorrhea" group

amenorrnea group		Early se		No ea		P-value
Demographic characteristi	ics	N=19	13%	N=126	87%	
Age at survey	40 - 49	9	47%	71	56%	0.80
	50 - 59	7	39%	37	29%	
	60 - 69	3	16%	16	13%	
	70 - 79	0	0%	2	2%	
Age at diagnosis	20 - 24	7	37%	17	13%	0.04
	25 - 29	4	21%	32	25%	
	30 - 34	1	5%	33	26%	
	35 - 39	7	37%	44	35%	
Race/ ethnicity	Non-Hispanic white	5	26%	23	18%	0.44
	Non-Hispanic black	12	63%	94	75%	
	Other	2	11%	9	7%	
Current marital status	Married	6	32%	56	45%	< 0.01
	Never married	11	58%	24	19%	
	Other ²	2	11%	45	36%	
Education	High school or less	9	53%	38	31%	0.10
	More than high school	8	47%	86	69%	
Annual household income	Less than \$20,000	5	29%	43	37%	0.69
	\$20,000 - \$39,999	5	29%	20	17%	
	\$40,000 - \$69,999	3	18%	21	18%	
	\$70,000 or more	4	24%	33	28%	
Current insurance	Private	8	44%	57	51%	0.43
	Medicare	3	17%	29	26%	
	Medicaid	7	39%	26	23%	
Health and medications						
BILD score	0	6	32%	32	25%	0.38
	1	1	5%	24	19%	
	2-3	6	32%	44	35%	
	≥ 4	6	32%	26	21%	

Kidney transplant	Yes	2	11%	1	1%	0.05
	No	17	89%	125	99%	
Dialysis for > 6 months	Yes	1	5%	4	3%	0.44
	No	18	95%	120	97%	
Hydroxychloroquine	Yes	9	82%	76	81%	1.00
	No	2	18%	18	19%	
Methotrexate	Yes	7	37%	21	18%	0.07
	No	12	63%	99	83%	
Mycophenolate mofetil	Yes	3	16%	9	8%	0.37
	No	16	84%	108	92%	
Steroids	Yes	12	92%	96	90%	1.00
	No	1	8%	11	10%	

This group includes women who reported no early amenorrhea and those who reported early amenorrhea was experienced due to a hysterectomy.

¹Includes separated, divorced, and living with a partner (not married)